SG10201908848RA - Pharmacologically induced transgene ablation system - Google Patents
Pharmacologically induced transgene ablation systemInfo
- Publication number
- SG10201908848RA SG10201908848RA SG10201908848RA SG10201908848RA SG 10201908848R A SG10201908848R A SG 10201908848RA SG 10201908848R A SG10201908848R A SG 10201908848RA SG 10201908848R A SG10201908848R A SG 10201908848RA
- Authority
- SG
- Singapore
- Prior art keywords
- transgene
- pharmacologically induced
- ablating
- replication
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
- C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
Abstract
OF THE INVENTION PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, 10 either permanently or temporarily, in response to a pharmacological agent - preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as "PITA" (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a 15 therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned offby administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript. 20 Figure for publication: None 126
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31875210P | 2010-03-29 | 2010-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201908848RA true SG10201908848RA (en) | 2019-10-30 |
Family
ID=44148714
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201908848R SG10201908848RA (en) | 2010-03-29 | 2011-03-28 | Pharmacologically induced transgene ablation system |
SG10201502270TA SG10201502270TA (en) | 2010-03-29 | 2011-03-28 | Pharmacologically induced transgene ablation system |
SG2012065868A SG183929A1 (en) | 2010-03-29 | 2011-03-28 | Pharmacologically induced transgene ablation system |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201502270TA SG10201502270TA (en) | 2010-03-29 | 2011-03-28 | Pharmacologically induced transgene ablation system |
SG2012065868A SG183929A1 (en) | 2010-03-29 | 2011-03-28 | Pharmacologically induced transgene ablation system |
Country Status (11)
Country | Link |
---|---|
US (1) | US20130023033A1 (en) |
EP (1) | EP2553106A2 (en) |
JP (1) | JP5922095B2 (en) |
KR (1) | KR20130040844A (en) |
CN (1) | CN102869779A (en) |
AU (1) | AU2011238708B2 (en) |
BR (1) | BR112012024934A2 (en) |
CA (1) | CA2793633A1 (en) |
MX (1) | MX342858B (en) |
SG (3) | SG10201908848RA (en) |
WO (1) | WO2011126808A2 (en) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9315825B2 (en) * | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
IN2014DN08812A (en) | 2012-04-18 | 2015-05-22 | Philadelphia Children Hospital | |
TWI775096B (en) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | Treatment of amd using aav sflt-1 |
WO2013188316A1 (en) * | 2012-06-11 | 2013-12-19 | Avalanche Biotechnologies, Inc. | Optical regulation of gene expression in the retina |
CN103088009B (en) * | 2013-02-18 | 2014-09-03 | 中国科学院微生物研究所 | Polypeptide and application thereof in regulating protein accumulation degree by micromolecules |
US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
KR102346455B1 (en) | 2013-03-15 | 2022-01-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Compositions and methods for treating mpsi |
US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
CN103352053A (en) * | 2013-07-11 | 2013-10-16 | 江苏省原子医学研究所 | Exogenous-gene removable slow virus controlled expression carrier system and application |
EP2843414B1 (en) * | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker for statin treatment stratification in heart failure |
PT3116900T (en) | 2014-03-09 | 2020-10-08 | Univ Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency |
SG10201810150UA (en) | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
EP3919508A1 (en) | 2014-04-25 | 2021-12-08 | The Trustees of The University of Pennsylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
WO2015164723A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
CA2966620A1 (en) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2016098078A2 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
AU2016226289B2 (en) | 2015-03-02 | 2021-04-29 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
WO2016176191A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Dual aav vector system for crispr/cas9 mediated correction of human disease |
US10662440B2 (en) | 2015-06-19 | 2020-05-26 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
WO2017015637A1 (en) | 2015-07-22 | 2017-01-26 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
JP6978407B2 (en) | 2015-08-06 | 2021-12-08 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Its use in compositions for treating GLP-1 and metabolic disorders |
MX2018002339A (en) | 2015-08-25 | 2018-12-19 | Univ Duke | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases. |
AU2016315699B2 (en) | 2015-08-31 | 2021-09-09 | The Trustees Of The University Of Pennsylvania | AAV-EPO for treating companion animals |
WO2017053732A2 (en) | 2015-09-24 | 2017-03-30 | The Trustees Of The University Of Pennsylvania | Composition and method for treating complement-mediated disease |
WO2017062750A1 (en) | 2015-10-09 | 2017-04-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful in treating stargardt's disease and other ocular disorders |
EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
KR20180100304A (en) | 2015-10-28 | 2018-09-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Intra-spinal administration of adeno-associated-viral vectors for gene therapy |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
US10889832B2 (en) | 2015-12-11 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
CN109069668B (en) | 2015-12-14 | 2023-04-18 | 宾夕法尼亚州大学信托人 | Gene therapy for eye diseases |
JP7061067B2 (en) | 2015-12-14 | 2022-04-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Composition for the treatment of Crigler-Najer syndrome |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
MA43968A (en) | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I |
MX2018012537A (en) | 2016-04-15 | 2019-02-25 | Univ Pennsylvania | Gene therapy for treating hemophilia a. |
CN109661470A (en) | 2016-04-15 | 2019-04-19 | 宾夕法尼亚州大学信托人 | New A AV8 mutant capsids and composition containing it |
US11191847B2 (en) | 2016-04-15 | 2021-12-07 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia B |
IL305449A (en) | 2016-04-15 | 2023-10-01 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
KR102392236B1 (en) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | Regulatory Polynucleotides |
SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
KR20230062878A (en) | 2016-07-08 | 2023-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Methods and compositions for treatment of disorders and diseases involving rdh12 |
WO2018022511A1 (en) | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
IL305149A (en) | 2016-07-26 | 2023-10-01 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
WO2018050783A1 (en) * | 2016-09-14 | 2018-03-22 | Ruprecht-Karls-Universität | Adeno-associated virus (aav) based regulatory system |
TW201819398A (en) | 2016-09-28 | 2018-06-01 | 美商寇峇有限公司 | Therapeutic peptides |
JP7065852B2 (en) | 2016-12-01 | 2022-05-12 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Pharmaceutical composition for the treatment of retinal degenerative diseases |
BR112019013576A2 (en) | 2016-12-30 | 2020-02-04 | Univ Pennsylvania | gene therapy for the treatment of phenylketonuria |
US11473106B2 (en) | 2016-12-30 | 2022-10-18 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating Wilson's disease |
WO2018144709A2 (en) | 2017-02-01 | 2018-08-09 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating citrullenemia |
WO2018152485A1 (en) | 2017-02-20 | 2018-08-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
WO2018156892A1 (en) | 2017-02-23 | 2018-08-30 | Adrx, Inc. | Peptide inhibitors of transcription factor aggregation |
SG11201907714UA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
JOP20190200A1 (en) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | Compositions useful in treatment of spinal muscular atrophy |
CA3052487A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
US11564996B2 (en) | 2017-03-01 | 2023-01-31 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
US11879133B2 (en) | 2017-04-24 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
CN110913866A (en) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS) |
WO2018209205A1 (en) | 2017-05-11 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for neuronal ceroid lipofuscinoses |
EP3630986A4 (en) | 2017-05-31 | 2021-08-11 | The Trustees of The University of Pennsylvania | Gene therapy for treating peroxisomal disorders |
EP3634978A1 (en) | 2017-06-07 | 2020-04-15 | Adrx, Inc. | Tau aggregation inhibitors |
US11827898B2 (en) | 2017-06-14 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
CA3068328A1 (en) | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
TWI835747B (en) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | Gene therapy for treating mucopolysaccharidosis type ii |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
JP7502991B2 (en) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | Treatment of amyotrophic lateral sclerosis (ALS) |
WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | Fully-human post-translationally modified antibody therapeutics |
KR20200104307A (en) | 2017-11-30 | 2020-09-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Gene therapy for mucopolysaccharide type IIIA |
EP3717652A4 (en) | 2017-11-30 | 2021-11-24 | The Trustees of the University of Pennsylvania | Gene therapy for mucopolysaccharidosis iiib |
US11629198B2 (en) | 2017-12-05 | 2023-04-18 | The Trustees Of The University Of Pennsylvania | Fusion proteins and antibodies targeting human red blood cell antigens |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
WO2019183634A1 (en) * | 2018-03-23 | 2019-09-26 | Inscopix, Inc. | Reagent coated lenses |
CN113164762A (en) | 2018-05-09 | 2021-07-23 | 生物马林药物股份有限公司 | Method for treating phenylketonuria |
TW202005978A (en) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | Novel liver targeting adeno-associated viral vectors |
CN108841868A (en) * | 2018-05-31 | 2018-11-20 | 康霖生物科技(杭州)有限公司 | A kind of gene order construct for Treatment of Central Nervous System Diseases |
JP2022512589A (en) | 2018-10-01 | 2022-02-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Composition useful for the treatment of GM1 gangliosidosis |
AU2020216135A1 (en) | 2019-01-28 | 2021-08-05 | Cohbar, Inc. | Therapeutic peptides |
KR20210131370A (en) | 2019-02-22 | 2021-11-02 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Recombinant adeno-associated virus for the treatment of GRN-associated adult-onset neurodegeneration |
KR20210132095A (en) | 2019-02-26 | 2021-11-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Compositions useful for the treatment of Krabe's disease |
CN110423281B (en) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | Fusion protein, viral vector and drug for treating age-related macular degeneration |
TW202140791A (en) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | Methods of treating phenylketonuria |
EP4096721A1 (en) | 2020-02-02 | 2022-12-07 | The Trustees of The University of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
US20230089312A1 (en) * | 2020-02-25 | 2023-03-23 | University Of Massachusetts | Inducible single aav system and uses thereof |
US20230304034A1 (en) | 2020-05-12 | 2023-09-28 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
AU2021271635A1 (en) | 2020-05-12 | 2023-01-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
JP2023531451A (en) | 2020-06-17 | 2023-07-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Compositions and methods for treatment of gene therapy patients |
EP4179097A1 (en) | 2020-07-13 | 2023-05-17 | The Trustees of The University of Pennsylvania | Compositions useful for treatment of charcot-marie-tooth disease |
AU2021325954A1 (en) | 2020-08-14 | 2023-03-02 | The Trustees Of The University Of Pennsylvania | Novel AAV capsids and compositions containing same |
MX2023002293A (en) | 2020-08-24 | 2023-05-19 | Univ Pennsylvania | Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases. |
BR112023002904A2 (en) | 2020-08-26 | 2023-04-25 | Univ Pennsylvania | RECOMBINANT ADENO-ASSOCIATED VIRUS TO TREAT ADULT-ONCEIVE NEURODEGENERATION ASSOCIATED WITH GRN |
IL301643A (en) | 2020-10-07 | 2023-05-01 | Regenxbio Inc | Gene therapy for ocular manifestations of cln2 disease |
US20230365955A1 (en) | 2020-10-09 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
IL302127A (en) | 2020-10-18 | 2023-06-01 | Univ Pennsylvania | Improved adeno-associated virus (aav) vector and uses therefor |
WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
TW202233844A (en) | 2020-10-29 | 2022-09-01 | 賓州大學委員會 | Aav capsids and compositions containing same |
US20240024507A1 (en) | 2020-12-01 | 2024-01-25 | The Trustees Of The University Of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
JP2023551911A (en) | 2020-12-01 | 2023-12-13 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Compositions and uses thereof for the treatment of Angelman syndrome |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
EP4323520A1 (en) | 2021-04-12 | 2024-02-21 | The Trustees of The University of Pennsylvania | Compositions useful for treating spinal and bulbar muscular atrophy (sbma) |
EP4334334A1 (en) | 2021-04-23 | 2024-03-13 | The Trustees of The University of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
AR125467A1 (en) | 2021-04-27 | 2023-07-19 | Univ Pennsylvania | PIG DERIVED ADENO ASSOCIATED VIRUS CAPSIDS AND THEIR USES |
TW202325845A (en) | 2021-10-02 | 2023-07-01 | 賓州大學委員會 | Novel aav capsids and compositions containing same |
AU2022373653A1 (en) * | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
WO2023102517A1 (en) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
TW202338086A (en) | 2022-01-10 | 2023-10-01 | 賓州大學委員會 | Compositions useful in treatment of metachromatic leukodystrophy |
TW202340467A (en) | 2022-01-10 | 2023-10-16 | 賓州大學委員會 | Compositions and methods useful for treatment of c9orf72-mediated disorders |
WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
WO2023196893A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating her2 positive metastatic breast cancer and other cancers |
WO2023201308A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Gene therapy for treating an ocular disease |
WO2023205610A2 (en) | 2022-04-18 | 2023-10-26 | Regenxbio Inc. | Hybrid aav capsids |
WO2024015966A2 (en) | 2022-07-15 | 2024-01-18 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US318755A (en) | 1885-05-19 | Attachment foe sewing machines | ||
US622349A (en) | 1899-04-04 | Wiliielm halstenbach | ||
GB1590524A (en) | 1976-11-24 | 1981-06-03 | Nat Res Dev | Assay of immune complexes |
US4210622A (en) | 1977-09-07 | 1980-07-01 | National Research Development Corporation | Kit for assay of immune complexes |
US4331649A (en) | 1978-10-10 | 1982-05-25 | Burroughs Wellcome Co. | Immune complex assay |
EP0091760B1 (en) | 1982-04-09 | 1986-07-02 | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. | Anti immune complex antibody and preparation thereof |
US4886876A (en) | 1983-03-31 | 1989-12-12 | Scripps Clinic And Research Foundation | Factor VIII coagulant polypeptides |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
WO1985001961A1 (en) | 1983-10-28 | 1985-05-09 | Genetics Institute | Production of factor viii and related products |
US5045455A (en) | 1984-01-12 | 1991-09-03 | Chiron Corporation | Factor VIII:C cDNA cloning and expression |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
IL74909A (en) | 1984-04-20 | 1992-01-15 | Genentech Inc | Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein |
EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
US4753893A (en) | 1985-05-31 | 1988-06-28 | Biostar Medical Products, Inc. | Method and article for detection of immune complexes |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
FI98829C (en) | 1986-01-27 | 1997-08-25 | Chiron Corp | Process for Preparation of Recombinant Protein Complex with Human Factor VIII: C Activity |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
FR2619314B1 (en) | 1987-08-11 | 1990-06-15 | Transgene Sa | FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
EP0500734B1 (en) | 1989-11-17 | 1998-02-11 | Novo Nordisk A/S | Protein complexes having factor viii:c activity and production thereof |
SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
SE468050C (en) | 1991-03-15 | 1998-04-27 | Pharmacia & Upjohn Ab | Recombinant human factor VIII derivative |
CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
AU5602394A (en) | 1992-11-13 | 1994-06-08 | Duke University | Chimeric blood coagulation proteins |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
NZ261277A (en) | 1993-02-05 | 1997-04-24 | Laporte Group Australia Ltd | Slag defoaming composition comprising a carbon source; an exothermic material (eg aluminium) and a dense inert granular material (eg calcium silicate) |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US6140120A (en) | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
JP3824633B2 (en) | 1993-02-12 | 2006-09-20 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ | Regulatory transcription of target genes and other biological consequences |
US20020173474A1 (en) | 1993-02-12 | 2002-11-21 | President And Fellows Of Harvard College | Methods & materials involving dimerization-mediated regulation of biological events |
ATE272122T1 (en) | 1993-06-10 | 2004-08-15 | Bayer Ag | VECTORS AND CELL LINES OF MAMMALS WITH INCREASED PRODUCTIVITY |
US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
US6476200B1 (en) | 1994-06-27 | 2002-11-05 | The Johns Hopkins University | Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion |
US6492106B1 (en) | 1994-06-27 | 2002-12-10 | The Johns Hopkins University | Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6133456A (en) | 1994-08-18 | 2000-10-17 | Ariad Gene Therapeutics, Inc. | Synthetic multimerizing agents |
US6150527A (en) | 1994-08-18 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Synthetic multimerizing agents |
ATE299145T1 (en) | 1994-08-18 | 2005-07-15 | Ariad Gene Therapeutics Inc | NEW MULTIMERIZING REAGENT |
JPH08178926A (en) | 1994-10-25 | 1996-07-12 | Sumitomo Pharmaceut Co Ltd | Immunoassay plate and use thereof |
EP0805819B1 (en) | 1994-12-29 | 2012-02-08 | Massachusetts Institute Of Technology | Chimeric dna-binding proteins |
US6326166B1 (en) | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
AU6486196A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
CA2244363C (en) | 1996-02-28 | 2006-11-14 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains |
AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
JP4135120B2 (en) | 1997-04-14 | 2008-08-20 | セル ジェネシス,インコーポレーテッド | Method for increasing the efficiency of recombinant AAV production |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
JP2003524368A (en) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | Fusion protein comprising a dimerization domain, a trimerization domain or a tetramerization domain and a complementary heterologous transcriptional activation domain, a transcription repression domain, a DNA binding domain or a ligand binding domain |
US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
AU752129B2 (en) | 1997-08-27 | 2002-09-05 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
AU766513B2 (en) | 1998-02-13 | 2003-10-16 | Board Of Trustees Of The Leland Stanford Junior University | Novel dimerizing agents, their production and use |
EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US7109317B1 (en) | 1998-11-06 | 2006-09-19 | President And Fellows Of Harvard College | FK506-based regulation of biological events |
WO2000028004A1 (en) | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
GB9917512D0 (en) | 1999-07-26 | 1999-09-29 | Univ Southampton | Data and/or video communications |
JP4827353B2 (en) | 1999-08-09 | 2011-11-30 | ターゲティッド ジェネティクス コーポレイション | Increased expression of single-stranded heterologous nucleotide sequences from recombinant viral vectors by designing sequences to form intrastrand base pairs |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
US20030013189A1 (en) | 2000-04-28 | 2003-01-16 | Wilson James M. | Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream |
DE10023887A1 (en) * | 2000-05-17 | 2001-11-29 | Axel Haverich | Nucleic acid construct for transient cell transfection, useful ,e.g., in gene therapy, contains recombinase gene controlled by inducible promoter and flanking recombinase sites |
JP2004501113A (en) | 2000-06-01 | 2004-01-15 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Methods and formulations for controlled release of recombinant parvovirus vectors |
DE10110449A1 (en) * | 2001-03-05 | 2002-09-19 | Lisa Wiesmueller | Test system for the determination of genotoxicity |
NZ545697A (en) * | 2001-05-30 | 2008-06-30 | Glaxo Group Ltd | A lambda-intR mutein comprising a glutamic acid to arginine change at position 174 of Wt lambda-intR |
JP2003033179A (en) * | 2001-07-05 | 2003-02-04 | Asahi Kasei Corp | Vector for reversible transduction of gene |
JP2004538005A (en) | 2001-08-08 | 2004-12-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Method for purifying a viral vector having a protein binding to sialic acid |
NZ600121A (en) | 2001-11-13 | 2013-12-20 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
AU2002359284A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
DE60310297T2 (en) | 2002-04-29 | 2007-06-06 | Trustees Of The University Of Pennsylvania | Method for direct recovery and amplification of integrated viruses from cellular tissue DNA |
US7247328B2 (en) | 2002-05-31 | 2007-07-24 | Zinpro Corporation | Chromium (III) alpha amino acid complexes |
WO2003104413A2 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Production of pseudotyped recombinant aav virions |
AU2003265855A1 (en) | 2002-08-28 | 2004-03-19 | University Of Florida | Modified aav |
WO2004048583A2 (en) * | 2002-11-22 | 2004-06-10 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
WO2004108922A2 (en) | 2003-04-25 | 2004-12-16 | The Trustees Of The University Of Pennsylvania | Use of aav comprising a capsid protein from aav7 or aav8 for the delivery of genes encoding apoprotein a or e genes to the liver |
JP5054975B2 (en) | 2003-09-30 | 2012-10-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Syngeneic strains of adeno-associated virus (AAV), sequences, vectors containing them and uses thereof |
US7273266B2 (en) | 2004-04-14 | 2007-09-25 | Lexmark International, Inc. | Micro-fluid ejection assemblies |
US7638119B2 (en) * | 2004-12-02 | 2009-12-29 | Wisconsin Alumni Research Foundation | Method of diminishing the symptoms of neurodegenerative disease |
US20080274093A1 (en) * | 2004-12-02 | 2008-11-06 | Johnson Jeffrey A | Method of diminishing the symptoms of neurodegenerative disease |
JP5702519B2 (en) | 2005-04-07 | 2015-04-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | How to increase the function of an AAV vector |
CN100513623C (en) | 2005-04-21 | 2009-07-15 | 中国科学院物理研究所 | Cerium-based non-crystalline metal plastics |
JP4495210B2 (en) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | Amplitude error compensator and orthogonality error compensator |
US20090317417A1 (en) | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
ES2400235T3 (en) | 2006-04-28 | 2013-04-08 | The Trustees Of The University Of Pennsylvania | AAV scalable production method |
US9388425B2 (en) * | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
JP2009171880A (en) * | 2008-01-23 | 2009-08-06 | Yokohama City Univ | Development of next-generation gene therapy and immunotherapy in alzheimer's disease |
JP2009171890A (en) * | 2008-01-24 | 2009-08-06 | Tsukishima Foods Industry Co Ltd | Antioxidant bread and confectionery |
WO2009146179A1 (en) * | 2008-04-15 | 2009-12-03 | University Of Iowa Research Foundation | Zinc finger nuclease for the cftr gene and methods of use thereof |
US9408008B2 (en) | 2014-02-28 | 2016-08-02 | Sonos, Inc. | Playback zone representations |
US20160120174A1 (en) | 2014-10-29 | 2016-05-05 | Ronald Steven Cok | Imprinted multi-layer biocidal particle structure |
-
2011
- 2011-03-28 US US13/638,015 patent/US20130023033A1/en not_active Abandoned
- 2011-03-28 CN CN2011800180140A patent/CN102869779A/en active Pending
- 2011-03-28 EP EP11713419A patent/EP2553106A2/en not_active Withdrawn
- 2011-03-28 AU AU2011238708A patent/AU2011238708B2/en not_active Ceased
- 2011-03-28 SG SG10201908848R patent/SG10201908848RA/en unknown
- 2011-03-28 SG SG10201502270TA patent/SG10201502270TA/en unknown
- 2011-03-28 JP JP2013502701A patent/JP5922095B2/en not_active Expired - Fee Related
- 2011-03-28 MX MX2012011374A patent/MX342858B/en active IP Right Grant
- 2011-03-28 CA CA2793633A patent/CA2793633A1/en active Pending
- 2011-03-28 KR KR1020127028151A patent/KR20130040844A/en not_active Application Discontinuation
- 2011-03-28 WO PCT/US2011/030213 patent/WO2011126808A2/en active Application Filing
- 2011-03-28 SG SG2012065868A patent/SG183929A1/en unknown
- 2011-03-28 BR BR112012024934A patent/BR112012024934A2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX342858B (en) | 2016-10-13 |
KR20130040844A (en) | 2013-04-24 |
JP5922095B2 (en) | 2016-05-24 |
WO2011126808A2 (en) | 2011-10-13 |
WO2011126808A9 (en) | 2012-08-16 |
AU2011238708A1 (en) | 2012-09-27 |
WO2011126808A3 (en) | 2012-06-28 |
US20130023033A1 (en) | 2013-01-24 |
CA2793633A1 (en) | 2011-10-13 |
SG10201502270TA (en) | 2015-05-28 |
BR112012024934A2 (en) | 2016-12-06 |
CN102869779A (en) | 2013-01-09 |
MX2012011374A (en) | 2012-11-12 |
AU2011238708B2 (en) | 2016-02-11 |
JP2013529063A (en) | 2013-07-18 |
EP2553106A2 (en) | 2013-02-06 |
SG183929A1 (en) | 2012-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201908848RA (en) | Pharmacologically induced transgene ablation system | |
HRP20201973T1 (en) | Ligands modified by circular permutation as agonists and antagonists | |
NZ598348A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
WO2009073527A3 (en) | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases | |
BR112014010291A2 (en) | combinatorial liposome compositions for cancer therapy | |
MX2015005798A (en) | Combination therapy. | |
BR112014023374A2 (en) | glp-1 peptide compositions and preparation thereof | |
NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
JP2015518485A5 (en) | ||
WO2009003199A8 (en) | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | |
WO2013059737A3 (en) | Tissue treatment device and related methods | |
JP2012041342A5 (en) | ||
WO2008132723A3 (en) | Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system | |
JP2014519333A5 (en) | ||
MX2011012043A (en) | Pharmaceutical system for trans-membrane delivery. | |
WO2009065406A3 (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases | |
WO2009140269A3 (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
TN2014000345A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
BR112015024659A2 (en) | treatment of diabetes mellitus by long-acting insulin formulations | |
BR112012016783A2 (en) | "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy" | |
PT2459153E (en) | Pharmaceutical or cosmetic or dietetic composition for promoting a hair pigmentation effect | |
BR112013018598A2 (en) | pharmaceutical composition, method for treating heart disease, use of (s) -methyl-3- [4- (2-hydroxy-3- [4- (2-hydroxy-3-isopropylamino) propoxy] phenylpropionate, and method for control heart rate | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
BR112014021497A2 (en) | jcv-vlp based drug delivery system |